HighPoint Advisor Group LLC Boosts Holdings in IDEXX Laboratories, Inc. $IDXX

HighPoint Advisor Group LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 130.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,077 shares of the company’s stock after acquiring an additional 1,177 shares during the period. HighPoint Advisor Group LLC’s holdings in IDEXX Laboratories were worth $1,405,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of IDXX. Blalock Williams LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter valued at $590,000. Beacon Investment Advisory Services Inc. raised its stake in IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after purchasing an additional 6,710 shares during the last quarter. Nordea Investment Management AB lifted its holdings in IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after purchasing an additional 8,845 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after purchasing an additional 3,820 shares in the last quarter. Finally, Mediolanum International Funds Ltd boosted its stake in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after purchasing an additional 4,909 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 34,612 shares of company stock worth $22,525,070 over the last three months. 0.79% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $533.92 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 1-year low of $496.61 and a 1-year high of $769.98. The firm has a market capitalization of $42.12 billion, a P/E ratio of 39.32, a P/E/G ratio of 3.10 and a beta of 1.58. The business’s 50-day simple moving average is $578.69 and its 200-day simple moving average is $647.92.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the company earned $2.91 EPS. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.66 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Monday, April 27th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.